Bioventus secured preferred access for Blue Cross Blue Shield of Michigan Medicare Advantage and Commercial patients to DUROLANE, GELSYN-3 and SUPARTZ FX to treat knee osteoarthritis pain, active in 2020.
DUROLANE is a single-injection, GELSYN-3, a three-injection and SUPARTZ FX, a five-injection hyaluronic acid (HA)-based joint-fluid treatment. The products are among the four preferred choices for HA coverage under the medical benefit for PPO, HMO, Medicare Plus Blue PPO and BCN Advantage plans.
“Bioventus has the broadest HA portfolio available to patients and physicians in the U.S. and we are pleased to have secured preferred status for Blue Cross Blue Shield of Michigan Medicare Advantage and Commercial patients,” said John Nosenzo, Chief Commercial Officer, Bioventus. “DUROLANE, GELSYN-3 and SUPARTZ FX are proven to provide OA knee pain relief and allow patients to resume more active lives.”
As of 3Q19, the company agreed to a U.S. contract with UnitedHealthcare Employer & Individual commercial plans granting access to DUROLANE and GELSYN-3 for the same application.
Bioventus secured preferred access for Blue Cross Blue Shield of Michigan Medicare Advantage and Commercial patients to DUROLANE, GELSYN-3 and SUPARTZ FX to treat knee osteoarthritis pain, active in 2020.
DUROLANE is a single-injection, GELSYN-3, a three-injection and SUPARTZ FX, a five-injection hyaluronic acid (HA)-based joint-fluid...
Bioventus secured preferred access for Blue Cross Blue Shield of Michigan Medicare Advantage and Commercial patients to DUROLANE, GELSYN-3 and SUPARTZ FX to treat knee osteoarthritis pain, active in 2020.
DUROLANE is a single-injection, GELSYN-3, a three-injection and SUPARTZ FX, a five-injection hyaluronic acid (HA)-based joint-fluid treatment. The products are among the four preferred choices for HA coverage under the medical benefit for PPO, HMO, Medicare Plus Blue PPO and BCN Advantage plans.
“Bioventus has the broadest HA portfolio available to patients and physicians in the U.S. and we are pleased to have secured preferred status for Blue Cross Blue Shield of Michigan Medicare Advantage and Commercial patients,” said John Nosenzo, Chief Commercial Officer, Bioventus. “DUROLANE, GELSYN-3 and SUPARTZ FX are proven to provide OA knee pain relief and allow patients to resume more active lives.”
As of 3Q19, the company agreed to a U.S. contract with UnitedHealthcare Employer & Individual commercial plans granting access to DUROLANE and GELSYN-3 for the same application.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
